0001437749-12-006131.txt : 20120615 0001437749-12-006131.hdr.sgml : 20120615 20120614200258 ACCESSION NUMBER: 0001437749-12-006131 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120614 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120615 DATE AS OF CHANGE: 20120614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 12908658 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 pdl_8k-061412.htm FORM 8-K pdl_8k-061412.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):  June 14, 2012

PDL BioPharma, Inc.
 
(Exact name of Company as specified in its charter)
 
000-19756
(Commission File Number)
 
 
Delaware
94-3023969
(State or Other Jurisdiction of
(I.R.S. Employer Identification No.)
Incorporation)
  
 
932 Southwood Boulevard
Incline Village, Nevada  89451
(Address of principal executive offices, with zip code)
 
(775) 832-8500
(Company’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01 Other Events.
 
On June 14, 2012, PDL BioPharma, Inc. issued a press release announcing that it has paid the June 14, 2012, regular quarterly dividend payment.  The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
  
Description
99.1
  
Press Release

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
PDL BIOPHARMA, INC.
  
 
(Company)
  
       
 
By:
/s/ John P. McLaughlin  
   
John P. McLaughlin
  
   
President and Chief Executive Officer
  

 
Dated:  June 14, 2012
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit No.
  
Description
99.1
  
Press Release
 
 EX-99.1 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm
Exhibit 99.1
 
 
Contacts:
      
John McLaughlin
    Jennifer Williams
PDL BioPharma, Inc.
    Cook Williams Communications, Inc.
775-832-8500
    360-668-3701
john.mclaughlin@pdl.com
    jennifer@cwcomm.org
 
 
PDL BioPharma Completes Regular Quarterly Dividend Payment

INCLINE VILLAGE, NV, June 14, 2012 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 7, 2012, the record date.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.
 
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
 

# # #

 GRAPHIC 3 image.jpg begin 644 image.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#<` ME0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^*_GS_P""LO\`P5F@^",&O?LU_LU:_%_9 MK_9KU^"[^,=W!-IGQ#^(FESQSV_PKMIT,=QH.@W,9>*;XAS1,4NKI"R>#8VX MSXC95T7^0JYN;B\N)[R\GFNKNZFEN;JZN99)[BYN)W:6>>>>5FDFFFE9I)99 M&9Y'9G=BQ)K];X&X&^L^QSG.:/\`L_NU,#@:D?\`>.L,1B(/_EQLZ5)K]_I. M:]CRQKO:\(/7[4ET\HOOW[;;[?V#?\$FO^"L5K\?+30?V;_VCM<@L_C?8 MVT6G>`_'NI31P6OQ=M+6+;#I6KSR%(X/B1;P1C#DA/&4:-/%M\0+/#J?U+_P M5"D=-&^#FQW3.I^-,[69,@$9QSC/3)QU-?Q@?LY?`GXN?M&_%WPG\, M/@GH]_J7CG4[^"\M=0M9KBQL_"EG8W$,MSXNUO6K=2VA:1H),5W/J@/GI.+> MVTZ.ZU2YL;2X_NS\=?LD>(/B7^SI\.OAQ\1OB9>^//C)\./#<$%O\5]3LH]- M7Q-XC^QP0ZG+K>EV>]38:L+6UM9+QOM&L*;2WU6ZN+Z^?4$OO+\0,BRO)LQH M8C`5Z5*6-(O`G[2 MWPT\&^,M&FTK6])^*O@JSU'3;Z)71@?$>G;9(RP>"\L;N(K-;7,1EM;NVD26 M)Y(G!/\`2!_86B?]`;2O_!=:?_&:^#G5Y+:7NKWO_P`!G0?RO:#XN\5^%;Z+ M4O#7B37O#]_!(LD5WH^JWVG7".A!!\RTGB8C(Y5B5895@5)%?L'^QE^V7JWQ M'U:V^%/Q5N8)_%<]O(WA7Q4(X;5O$)LX&FGTC5X8ECMQK`MHI+BSO((XDU%( M9H)XEOQ%)?9G_!2/X?\`P^LO`?A7QQ;Z=I>C^.#XHM]!MYK"WM[2YUW1I].U M&ZO8;V*!(S=KIDUM:307V#A;U5K\F/`FL:AX>\;^$-=TIY8]2TCQ M-H6HV+0EED^U6>IVT\*KMY.]T",O1U8H00Q!+*K"]K/OU37G;5`?I]_P5$DD M2X^"^QW3,/CW(5F4'Y_"/)`(!([$].<=37Y-^?/_`,]I?^_C_P"-?K#_`,%1 M3^_^"W&/W/CWCT^?PC7P-^S;:VM]\?/A#9WMM;WEI<^/O#L-Q:W<,=Q;7$+W M\2O%-!,KQ2QN#AD=64CJ**6E-/\`Q/\`%@>,+&=%96!Z@@V1!![@\5^=7[ M^']/\*:YX7EM+GQ#IFB6\=CI&M:->7D-E<7`TN`)9V>I:?/=0W9N+.*!;BS6 M[2YCFE%M)$E5C)I..^G1K6V_S`Z+]D_]N)_BAJ]A\-_BI#8:=XSO\P^'O$EC M&MGI?B6Z4%AIM]9`F'3=:F12;1K8I8:E(#;0V]E=&V@N_',C((.".".XR#P:_GEL+^\TN^LM3T^XEL[_3KNVOK&[@8I-: MWEI,EQ;7$+CE)8)HTEC8*/"/PTUV=%` M58[G4O$7A.ZNHE`R`(KF26,`Y/)K^6^OZC_`(-?\D@^ M%?\`V3CP1_ZC.F4Z_P!C_M[]`/2:***YP"BBB@#^-_\`X*S_`/!*G5_V>M7U M_P#:/^`NFZEKOP+US49]3\;^&U>ZU36/A)J^IW)DGO'FF:>]U'P#J-Y.?LNJ MW$DUUX=NIETW5YI+62QU"?\`!>O]/S4-/L-6L+[2M5L;/4]+U.SN=/U+3=0M MH;VPU"PO87MKRQOK.Y22WN[.[MY)(+FVGCDAGAD>*5'1V4_QR?\`!5[_`()0 MZA^S?J&L_M"?L]Z->:G\`-3NVO/%GA.S6:]O_@W?WDW+H/WEQ=?#N[N)!'I^ MH2&2;PU-)'I6JR-:-87\_P"X\#<<+&*CDV<5;8M*-/!8RH],4E:,,/7D]L2E MI3J-_P"T*T9?O[.MQ5Z%KS@M-Y173S2[=7VWVV^%/^"?'[=WC3]A+XOR^,-* MTN'Q1\//&,>FZ+\4_!K1VL=_K.@V-S/+::AX?U29!+IOB+07O+N[TQ7G72]2 M\Z?3]4C$<\-]8?W#I^U/\'+GX"^'/VC+'Q#+<_#KQEH%IKOA)Y;*XL-;U]K^ M.1K71[/1[];>[&K&>*:WGAD58+4P7%U-<+80M=U_+C_P2>_X)/7O[0U[HG[1 M7[16B76G_`C3[J.^\%>"K^.6TO?C#>VDN8[V]C/ESVWPXMIX\3SC9+XME1K& MR9=)6[NY_P!M_P#@IM96>F>&?@AINFVEMI^G:?=>+;*PT^Q@BM+*RL[33_#% MO:VEI:0+'!;6UK`B0V\$,:100HL<2J@"U\UXCXK)<7FU*G@H\^94?W698JE) M>PDH)1IX>:2?M<312Y95(RBJ4;4)^TE'EH:8934?>^%ZQ777KY)]OGZ_`WQ; M_:)\<_%3XKV?Q6DFBT#5/#UW8R>"K6PBMY!X:M=(OVU'24$TT!_M&[AO&:\N M;J\CD6>ZDD"006@AM(ND_P"&T/VG/^BKZK_X)_"__P`HZ\C^$.@Z7XI^*WPU M\-:Y;&\T7Q!X\\)Z+JUH)I[_Z)N_\`X5WC7_YH:_/IRA#E3C?331.R^9TGX0?$+XJ?$/XK M:C:ZK\0O%>J>*+VQ@:VL3?O#';V,#L'E2SL;2*VL;4S.J-F3)RT_3[:& MSLK2!/N0VUK;I'!!$O\`#'$BJ,G`K.59B7YZ>@'Y-?\%1O^/CX M+?\`7'Q[_P"A^$:^#?V8_P#DX3X-_P#90O#7_IQBK[R_X*C?\?'P6_ZX^/?_ M`$/PC7Y7:)K>K>&]7TW7]!O[G2M9TB\AO],U*S?R[JRO+=Q)!WMNWB/Q[;0Z!H.D>:INYX M9+VVEU34F@!,B65A8Q3[KEE$7VV6TMMV^<"OQS;]JC]HIU*GXP^.`&&#MU9T M;GT=$5E/NI!'8UXUK_B/Q!XJU*;6?$VMZMXAU:XP)]3UK4+O5+Z506*J]U>R MS3%$+-L3?L0$A%`XJ(T6FFY+1IZ>6OD!C5^X_P`9]"O/#/\`P3PM=#U!&COM M/^'_`,+([R)@0T-S)XA\)SSP,#T:"25H6'JAKXA_9!_9.\1?%GQ3H_C;Q?I% MQIGPMT.\@U*6748'@/C*XM9%FM](TJ&4*]SIX'\[E?U'_ M``:_Y)!\*_\`LG'@C_U&=,K^7"O5K+XZ_&G3;*TT[3_BS\1K&PL+:"RL;*U\ M9:_!:V=G:Q+!;6MM!%?K'#!!"B10Q1JJ1QJJ*H4`5=2#G:SM:_XV_P`@/Z@J M*_F&_P"&@OCK_P!%C^)O_A;^(_\`Y8U[W^R]\:?B_P"(/C_\+M%UWXH>/M9T MC4?$:V]_I>I^+-.8;JTN;V6">,LJMLDC9=RJV,@$9.@TF^9:`?O M]1116`!534-/L-6L+[2M5L;34]+U.TN=/U+3=0MH;VPU"PO87MKRQOK.Y22W MN[2[MY)(+FVGCDAGAD>*5'1F4VZ*:;335TT[IK1IK9I]P*MC8V6F65GINFV= MKI^G:?:V]C86%C;Q6EE8V5I$EO:V=G:VZ1P6UK;01QPV]O#&D4,2)'&BHH4> M,?&KP)\"?'%OX>C^-P\,FWTZ;47\._\`"1^*9?#"^=4<1^9EO<:_G(_P""_C>%$U;]A>3QW#+<>"$^)OCD^,H8%O#<3>%! M<_#!O$4,`T]X]0,LND+=J@L9([POM^S.L_EL/7R++?[9S;"Y=*M4H_6?;MU: M=/VU1.CAJV(M&FYTU.4W2Y$G4CK*]]+$3ER0&-4T_5[*_T'QOK&O#3-3L+F.\T^XEC@\27UL'BN8$ MECCNHGCD*8:-URI]EM?C7\);WXI:C\$;3XB>$[GXO:1HZ>(-4^',.L6K^+K# M1)+>QNDU2ZT97-W#9/;:GI\ZSN@0QWENV<2KG^7#X!Z'^SEXQ_X*3_LXWO\` MP2_7QAX!\%>%U&K_`![?Q7XGUO1=(UKPO#>R-K6D:%H/C_Q#<^-/$?\`:OAU M+O3;[2XK:\M$U"ZTO4X+.RBT^_U6+]:_!WQ;^']W_P`%?_BI\(;?X!^`].^( M.E_!*QUZ_P#C_;ZCJ[>/-?]FT>S M8ON>1*]?'<-1PE6K!5<;6<,CJYNZ%:A0P6-P3IXB%!0Q^'J8FM%4W%^T2HU9 M5Y1G!JDDFW,:ETGHO?4;IMQE=?9=OEJDD]V?KI5:\O;/3K2YO]0N[:PL+*"6 MZO+V\GBM;2TMH$,D]Q)/B=\2O'2>%M/\7:_;27"2:?X-LA>:1&HO M!:S2Z5+<7^H/-8-::GJL&BQZA9VTLG_#<>A?MH?\$_?VZH;_`,$ZC\+?B]\( M?@U\7O!WQ=^%^KW8U&;P]K+^!_%=M!=6-\UM9376EWMYI&LV!BO+*UO].U'2 M;^PNHI8X[6^ON'_5G,Z;I2Q%.G3@ZV"I8J-/$8>MB558P]YQA-PE))TJD7M?K:Z:4N7>S:L[?\-<_1KQKX1_9Q_:#O=$LO%%[ MX*^(&H:$NH?V-9Z9XV5[RU34?LC7^RW\.Z[;S3+-]@M2QF24)Y(*;-S[OGCX MB?"7_@GU\)?%OPZ\!_$>P\+>$?%_Q;U<:#\-]!U7Q-XY2^\7:P=0TG21I^E" M'5YHFG.I:[I%F!/)"IFOX%#?,2O\L>F>&OV!-,_X)O:'\0%\92Z!^WW9:YJ, M^@6O@_Q;XO?Q5->0?$VZMM*CUSP\EU-X+]3TWQ M?\(+_0M)G2^5&C\7>)-/ATF"\;4(QGXL_H>_X8D_9@_Z)=:?^%'XP_\`F@KJ?#?[*G[/'A.[AO\` M1OA1X7^V6[B2&?58;OQ`T4BG*R1KK]WJ<<?3= M5E&I6\>B:H;&+19K&YU"PU**UN].F!/TO^T;\8?VYO#7Q#O/#'[./[._PI\3 M>!-)\/:/J=W\4OB]\48_"FE:OKNIO?FZ\,:'H-K-8ZB;C2X+6V:?4KBXDT]Y M+Z.,O"\3*WR=7),?1KT*%6I@X+$X;ZW0Q,LQP?U.K051T7*GBO;^QG-58NDZ M49.IS1;4'%^UNVM]C[XC1(D2*)$CCC18XXXU")&B`*B( MB@*J*H"JJ@!0```!7,>-?!/ACXB^&=2\'>,M*36O#FKBU&HZ;)<7=JEQ]BO+ M?4+7,]C<6MU&8;RUMYU,4Z$M&%;KXB_MGPQ?Z_X.\.:_K.GG3]?M86FCT[4[_P[JFD7B1_ MV@UG)837-I?ZC;7%M(?//V*_^"B'[2W[9?B?X6:IX<_99M-`^`]R?$FC?&OX MPW'B-WL-!\8Z?HVO:KI>C^`]-OKK3M1UFP@DC\(Z9K6IFPU5%U+6[^W\NPBT M^&YNJGP[FM*&/J5:5&E3RR:ABIU,7AH1C.=!XFE&E)U;5W7I)/#JCSNLYPC" M[D'M(OEM=\RNK)]TG?32S>M]K,^X_P#AB3]F#_HEUI_X4?C#_P":"C_AB3]F M#_HEUI_X4?C#_P":"OR<^'G_``5B_;&^.7PH^,/Q#^"_['_@;6;?X":EXCO_ M`(E^(M9^(MS;>&X/"NC:4NJ06/AO29O[*UWQ!XN^Q:=XBU75X;6X%IIVFP:* ML-M>WVKQVZV;O_@K=^U1XR_9RF_:O^$'['GAZ3X)>`(]-TWXM>(?''Q%C2]G M\4B]L+#Q%!\/='TLVFJWOA71KG5M*B/B:_L;N)O&KB4XO#PMSU-&HVU)]K#^]MS+W9:I; MM:=.I^K7_#$G[,'_`$2ZT_\`"C\8?_-!70^$_P!D[]G_`,#^(M)\6>%_A[;: M7X@T.Z^V:7J"ZWXFN6M;D1O$)5@O-:N+60A)'`6:&1><[<@$>8ZM^TM\5?'_ M`.RM\*OCY^RY\%(?BEXP^+UAX+U/2O`GB?Q?8>$M.\)Z;XETVYO=;U7Q+XAN M(TMI[+PE_LM_M7_``4^ M%_@C7?C7HFNW/PK\=_";QY+XS\,G7M(L]0N(]'\1Z?/=7%[&)KBQ^P32+>:; M;1R7,:]/%2A[!SPBQ+KX66,PT<8HX-.6)E'"NK[:<:4 M82;:A[RIS=/GY':W-*V^MK.SMKMK:VNR\S]@Z*^*O$?Q7_:XL(;"U\.?`KPW MKVH!C/J=_=ZAJ&D:2UEG M0ZAIFG2W5MHM]\,]6^Q1S:G/%&LM\FG301R"*>.%COF3;M5RBOI>$)\G$672 MY5+_`'N+C+FLXSP.)A)/E<9?#)ZJ2:9G6UIR_P"W?_2D>`:WXJ^,/_!4?]KS M]ESQC\*_@#IWP`T#]GCQC:>,/&WQ2OO'GA+4O&=YHD/B'PUJMU8R)H/]GZG> M06L&A2Z?X>TJ"VU:)M0\07TM_=Z;ILMVQ^M/`_A/7/\`A^Y\:_$L^GLOAZ^_ M9QL-/BOQ=V69)F\(_"J)T%LMR;Y/GAF3>]LJ[DW`[&1F**^GS'$O#8O-7<,8S#8:G%UJDU#%XG"8FM*=6M6JU9S=67NIS]G".D*:UOG&-TI-MMU M(R;TW22V22_"[ZL^0?@G\=?%O_!%;Q7\/IOB#\&?& M7@?Q5X5AN]:M[NR71K6+Q!IVJWT=]I27VFZ;HJ7KW,*W&DZK9ZJ+:TUJPNK2 M^KT[]F_]FKXQ:;^R-_P4X_:K^+.D:;X?\;?ME?#CXM>*O#'@+2-;TO58]*T* M\T;XB>(8KF[U&SNI-,CEU?5O%CV>G6TUX+BRT[2H[C4_LMQJ$MM;%%=&/Q MY%.RLKW2L6U^YBO*G^#C_D2_\%"/"^O:O_P4K_X)DZUIU@;G3-$\67,FIW/V MJRA^S)_PF/A^4MY-Q*4X&`"Q"U\3_`+6%]X<\`?\`!13XMW7[ M>7P9\<_M,^!_'5II%O\`LG>#]`^(6EV?A/0[*X%O;6MM=^&KOQCX9M](:1U? M3K^[U'RTCU9-5UEM,UG^TK748"BO9X?K2JSR3"27+"IPYF5/VM*=6AB::AF5 M?%]IW'[!?PT\9 M>!/@K_P6)\%Z]\.M*^'&J7WASQ2^E>`=`U[3]=T/PP+_`,#_`!G6U\'Z3K*: MA<"ZLO#RSVND6U_?2QBYBA2X:9P9'7]&O^",WA[4O#'_``3Y^%NE:O8K8:DG MB#XHSW4`FM;@DS_$#Q$T,C364Y-Z\V]W35G'RA-+_P`&+_(^&?\`@ESX M.\2:%^P+_P`%"-*U32S::EJ_B#XWOI]M]LTZ9KD7/P9M[:W'GVUY-;Q%IP8P M+B:((3O8JA+U@_!3P7XFM?\`@@;\6?"DVE%/$%ROC[RK`7FFL9/.^+.F3(QN MUO#9#]RI<[[E6`39C=M4E%>EB\74>/QLN6G>7%_#M9Z2LITL--12]Z_*[ZZM MOHT*,4HQW_A37WN+.)_:3\,_%[2?^"9O_!.K4Y;;Q'??L^>!H-"G_:H\!>$/ M&]EX0\0^*O##7.F-I>FQ:FFI6RW]G)86WBNP6"TEOA:ZOJNCZI)9/]A6[L?* M_ACX=^&?BO\`;A_8`^-7[,W[++_L_?L_ZMXUU;1-,O=5\6Z-JWB[QSK.CQV\ M.MZ]KFD0>,/$]QI5AI2Z]I>FZ3%+?W&I7\B:M?7*+'):1*45Z.#Q"LG:Z76R:UU/ZXJ***_'3J/__9 ` end